Astrana Health reported second quarter 2026 financial results with total revenue of $972.5 million, a 49% year-over-year increase, and net income attributable to Astrana of $19.7 million, up 109%. Adjusted EBITDA reached $68.9 million, rising 43%, while adjusted diluted EPS increased 45% to $0.80. For the first half of 2026, net cash provided by operating activities was $100.8 million and free cash flow totaled $92.9 million. The company raised its full-year 2026 Adjusted EBITDA guidance range to $255–$280 million from previous estimates. Additionally, Astrana appointed Daniel Rothman as President of Physician Enterprise and Vishal Gupta as Senior Vice President of Enterprise Transformation. Astrana Health operates in the healthcare industry, providing physician-centric, technology-enabled value-based care services.

Astrana Health, Inc. announced the retirement of Glenn Sobotka, Chief Accounting Officer and principal accounting officer, effective August 7, 2026. John Vong, currently Senior Vice President – Accounting, will succeed him as the principal accounting officer effective on that date. Astrana Health, Inc. operates in the healthcare industry and provides value-based care services.

At its Annual Meeting of Stockholders on June 10, 2026, Astrana Health, Inc. approved the Amended and Restated 2024 Equity Incentive Plan. This approval increases the number of common shares reserved for issuance under the plan by 1,000,000 shares and extends the plan's term until March 24, 2036. Other routine matters, including the election of nine directors, the ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation, were also approved. The company operates in the healthcare industry, providing value-based care services.